The race to find a cure for Alzheimer's disease has been a long and arduous journey, but a recent breakthrough by Professor Ursula Quitterer and her team at ETH Zurich offers a glimmer of hope. Their research, spanning almost two decades, has led to the development of Compound 10, a chemical compound that could potentially slow down the progression of Alzheimer's disease. This is a significant finding, as current medications only delay the disease's progression by a few months, offering little in the way of long-term relief.
The key to this discovery lies in the enzyme GRK2, which plays a crucial role in many human cells, including the brain. Quitterer's team found that the inactivated form of GRK2 occurs in large quantities in the brain tissue of dementia patients and in a mouse model of Alzheimer's disease. They discovered that this inactive form forms aggregates that deposit on and damage the mitochondria, the cell's powerhouses, leading to a reduction in energy supply and cellular stress. These aggregates also promote the production of amyloid beta, a protein fragment considered a main cause of Alzheimer's, creating a vicious cycle that accelerates the disease's progression.
To break this cycle, Quitterer and her colleagues developed Compound 10, which prevents GRK2 molecules from forming aggregates. This leads to improved mitochondrial function, reduced amyloid beta deposition, and the preservation of nerve cell function. The compound's effects were not limited to the brain; it also positively influenced heart function and aging processes, as evidenced by the mice's reduced grey hair in old age.
The research took so long because Alzheimer's is an age-related disease, and the team worked with older animals. The slow pace of experimentation, with each experiment taking about 1.5 to 2 years to complete, is a challenge in a field where time is of the essence. Despite the delays, Quitterer remains optimistic, emphasizing the importance of identifying a new target protein and an active ingredient that operates via a different mechanism than existing Alzheimer's drugs.
The next steps involve finding a company interested in developing Compound 10 into a drug. This is a crucial phase, as it will determine whether the compound can be translated from the laboratory to real-world applications. Quitterer's research offers a promising avenue for improving the quality of life for Alzheimer's patients, and the potential impact on the field of neuroscience is immense. The journey towards a cure for Alzheimer's is far from over, but with discoveries like Compound 10, there is reason to believe that we are moving in the right direction.
